Physicians' Academy for Cardiovascular Education

Heart Failure

Follow the news, literature, and elearning on new developments in the management of Heart Failure.

Optimizing RAASi therapy: The role of personalized therapy

10' education - July 5, 2022 - Prof. George Bakris, MD and prof. Giuseppe Rosano, MD, PhD

Benefits and evolving insights on SGLT2i in the spectrum of LVEF

10' education - June 29, 2022 - Prof. Carolyn Lam, MD, PhD

Management of high risk patients with HFrEF

10' education - June 28, 2022 - Prof. Javed Butler, MD and Shelley Zieroth, MD

Guidelines, RAASi and hyperkalemia: the clinical dilemmas in heart failure

10' education - June 21, 2022 - Prof. Andrew Coats, MD

The clinical challenges of initiating guideline recommended therapy in HF

10' education - June 21, 2022 - Prof. John McMurray, MD

The future of heart failure management: rethinking approaches to care

10' education - June 21, 2022 - Ileana L. Piña, MD, Javed Butler, MD, Marco Metra, MD, and Giuseppe M.C. Rosano, MD, PhD

Clinical implications of ESC/HFA guideline updates for iron deficiency in heart failure

10' education - June 13, 2022 - Javed Butler, MD and Piotr Ponikowski, MD, PhD

Optimizing RAASi therapy in patients with HF and multiple comorbidities

10' education - May 31, 2022 - Gregg Fonarow, MD and Andrew Coats, MD

Managing hyperkalemia in HF: Navigating the evolving clinical landscape

10' education - May 16, 2022 - Keith C. Ferdinand, MD and Marco Metra, MD

EHR-based intervention improves quality care for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD

Optimization of RAASi and low risk of hyperkalemia with potassium binder in HFrEF

3' education - Apr. 4, 2022 - Prof. Javed Butler, MD

Updates in the new AHA/ACC/HFSA heart failure guideline

3' education - Apr. 3, 2022 - Prof. Paul Heidenreich, MD

Does adding salt to an egg harm HF patients?

3' education - Apr. 3, 2022 - Joseph Cleveland, MD

Study on effects of low-sodium diet on clinical events in HF

3' education - Apr. 2, 2022 - Prof. Justin Ezekowitz

What clinical data support the practical use of potassium binders?

10' education - Mar. 16, 2022 - Prof. Peter van der Meer, MD, PhD

The renal tamponade hypothesis

5' education - Mar. 15, 2022 - Eva Boorsma, MD

Mode of action of potassium binders

10' education - Mar. 1, 2022 - Joost Beusekamp, MD, PhD

Outcomes, pathophysiology and management of iron deficiency in HF

10' education - Feb. 22, 2022 - Robert Mentz, MD and prof. Peter van der Meer, MD, PhD

Which patients benefit from potassium binders?

10' education - Feb. 15, 2022 - Kevin Damman, MD, PhD

Role of a non-steroidal MRA in the treatment spectrum of patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

Prognostic value of epicardial adipose tissue in patients with HFmrEF and HFpEF

5' education - Feb. 1, 2022 - Gijs van Woerden, MD

The clinical dilemma of RAASi therapy and hyperkalemia

10' education - Oct. 20, 2021 - Prof. Javed Butler, MD - Online CME

RAASi as a fundamental pillar in HF

10' education - Oct. 4, 2021 - Prof. Andrew Coats, MD - Online CME

Risks associated with hyperkalemia

10' education - Sep. 16, 2021 - Prof. Stefan Anker, MD, PhD - Online CME

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD

What is new in the 2021 ESC HF guidelines regarding patients with EF>40%?

3' education - Aug. 27, 2021 - Prof. Carolyn Lam, MD, PhD

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD

Another chapter in the SGLT2i book

3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD

Phenotypic clusters in HFpEF

5' education - July 28, 2021 - Alicia Uijl, PhD

Optimizing RAASi therapy: The role of personalized therapy

10' education - July 5, 2022 - Prof. George Bakris, MD and prof. Giuseppe Rosano, MD, PhD
Prof. Bakris and prof. Rosano examine the management of hyperkalemia in patients with HF and CKD, and provide individualized approaches for optimizing RAASi therapy. Collaboration between nephrologists and cardiologists is key, according to the discussants.

Prof. George Bakris and prof. Giuseppe Rosano examine the management of hyperkalemia in patients with HF and CKD, and provide individualized approaches for optimizing RAASi therapy. Collaboration between nephrologists and cardiologists is key, according to the discussants.

Benefits and evolving insights on SGLT2i in the spectrum of LVEF

10' education - June 29, 2022 - Prof. Carolyn Lam, MD, PhD
Prof. Lam talks about effects of SGLT2i in HF across the spectrum of LVEF and reviews current guideline treatment recommendations.

Prof. Lam talks about effects of SGLT2i in HF across the spectrum of LVEF and reviews current guideline treatment recommendations.

Management of high risk patients with HFrEF

10' education - June 28, 2022 - Prof. Javed Butler, MD and Shelley Zieroth, MD
Javed Butler and Shelley Zieroth talk about the effects and tolerability of SGLT2i and the oral soluble guanylate cyclase stimulator vericiguat in patients with HFrEF.

Javed Butler and Shelley Zieroth talk about the effects and tolerability of SGLT2i and the oral soluble guanylate cyclase stimulator vericiguat in patients with HFrEF.

Guidelines, RAASi and hyperkalemia: the clinical dilemmas in heart failure

10' education - June 21, 2022 - Prof. Andrew Coats, MD
Managing hyperkalemia while optimizing RAASi therapy in patients with heart failure can be challenging. Andrew Coats talks about this clinical dilemma.

Managing hyperkalemia while optimizing RAASi therapy in patients with heart failure can be challenging. Andrew Coats talks about this clinical dilemma.

The clinical challenges of initiating guideline recommended therapy in HF

10' education - June 21, 2022 - Prof. John McMurray, MD
Prof. McMurray talks about barriers and concerns regarding Prof. McMurray talks about barriers and concerns regarding initiating guideline recommended therapy in patients with heart failure.

Prof. McMurray talks about barriers and concerns regarding initiating guideline recommended therapy in patients with heart failure.

The future of heart failure management: rethinking approaches to care

10' education - June 21, 2022 - Ileana L. Piña, MD, Javed Butler, MD, Marco Metra, MD, and Giuseppe M.C. Rosano, MD, PhD
Ileana Piña, Javed Butler, Marco Metra and Giuseppe Rosano talk about ESC/HFA guideline updates, management strategies for recurrent hyperkalemia, and foundational therapy for patients with heart failure.

Ileana Piña, Javed Butler, Marco Metra and Giuseppe Rosano talk about ESC/HFA guideline updates, management strategies for recurrent hyperkalemia, and foundational therapy for patients with heart failure.

Smoking and its cessation similarly associated with HFpEF and HFrEF

Literature - June 15, 2022 - Ding N, et al. - J Am Coll Cardiol. 2022

Smoking is an important modifiable risk factor for HF. But to what extent does this apply to the 2 phenotypes of HF: HFrEF and HFpEF? And what is the effect of (long-term) smoking cessation? A recent analysis of the ARIC study offers valuable insights.

Clinical implications of ESC/HFA guideline updates for iron deficiency in heart failure

10' education - June 13, 2022 - Javed Butler, MD and Piotr Ponikowski, MD, PhD
Javed Butler and Piotr Ponikowski discuss the clinical significance of iron deficiency in patients with HFrEF, and take a close look at the key updates in the 2021 ESC/HFA guidelines.

Javed Butler and Piotr Ponikowski discuss the clinical significance of iron deficiency in patients with HFrEF, and take a close look at the key updates in the 2021 ESC/HFA guidelines.

Optimizing RAASi therapy in patients with HF and multiple comorbidities

10' education - May 31, 2022 - Gregg Fonarow, MD and Andrew Coats, MD
Gregg Fonarow and Andrew Coats review the key updates in the latest ESC/HFA heart failure guidelines and talk about strategies for maintaining optimal RAASi therapy in patients with heart failure and multiple comorbidities.

Gregg Fonarow and Andrew Coats review the key updates in the latest ESC/HFA heart failure guidelines and talk about strategies for maintaining optimal RAASi therapy in patients with heart failure and multiple comorbidities.

Decongestive effects of SGLT2i in acute HF

News - May 25, 2022

ESC Heart Failure 2022 An analysis of the EMPULSE trial investigated the decongestive effects of empagliflozin compared with placebo in addition to standard medical treatment.

Effects of SGLT2i on peak VO2 in patients with HFrEF

News - May 25, 2022

ESC Heart Failure 2022 A randomized clinical trial investigated the effect of dapagliflozin on maximal functional capacity at 1 and 3 months in patients with stable HFrEF.

Maintenance of lower potassium levels in HFrEF with potassium binder

News - May 24, 2022
In the DIAMOND trial, use of patiromer not only resulted in maintenance of lower levels of potassium compared with placebo, but also in a lower risk of hyperkalemia events in HFrEF patients on RAASi therapy.

ESC Heart Failure 2022 In the DIAMOND trial, use of patiromer not only resulted in maintenance of lower levels of potassium compared with placebo, but also in a lower risk of hyperkalemia events in HFrEF patients on RAASi therapy.